Atlas Trials

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Clinical trial NCT05401279 · UNKNOWN

Trial details

NCT number
NCT05401279
Sponsor
RenJi Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial Carcinoma BladderPD-1 Inhibitor
Start date
2022-06-01
Primary completion
2024-04-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.